RxDoctor Payments DataLook up a doctor →

Allen Ho, MD

Ophthalmology · Plymouth Meeting, PANPI 1922056712

Payments from drug & device makers

$1,302,095in general payments, 2019–2025

Across 251 payments — averaging $5187.63 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Genentech, Inc.$732K
  • Novartis$269K
  • Regeneron$91K
  • Aerie Pharmaceuticals, Inc.$37K
  • Alcon Research LLC$35K
  • AbbVie$30K
  • plus $108K from 20 others
$7,708in research payments, 2019–2025

Across 4 payments — averaging $1926.88 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • F. Hoffmann-la Roche AG$5K
  • Regeneron$2K

What the payments were for

  • Consulting fees$205,46991%
  • Speaking & faculty fees$6,2973%
  • Travel & lodging$6,9973%
  • Food & beverage$6,3313%
  • Gifts$1420%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,302,095 in reported general payments places this provider in the 95th percentile of 920 ophthalmology providers in Pennsylvania.

See all ophthalmology providers in Pennsylvania

Medicare billing

Part B allowed, 2024
$8,560,529
Medicare patients
1,505
Services billed
45,314

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Prednisolone Acetate199$11,021
ProlensaBromfenac Sodium17$5,966
Ketorolac Tromethamine210$4,826
Brimonidine Tartrate19$2,123
Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat50$920
Latanoprost43$562
Atropine Sulfate13$497
ErythromycinErythromycin Base34$374
Dorzolamide Hcl14$302
Polymyxin B Sul-TrimethoprimPolymyxin B Sulf/Trimethoprim27$229
Timolol Maleate22$211

Paid to pharmacies, not to this prescriber.

Other ophthalmology in Plymouth Meeting

See the full list for Pennsylvania

Where these figures come from

Is this you, or does something look wrong? →